Lobe Sciences Enters into an Exclusive Agreement With iNGENū to Conduct Clinical Trials in Australia
August 12, 2025
Learn moreAugust 12, 2025
Learn moreCompany profile: USA NASDAQ-listed biotech Phase: 1a SAD MAD & 1b Therapeutic Area: Psychedelic Neuroscience
Company profile: USA NASDAQ-listed biotech Phase: 1a SAD MAD & 1b Therapeutic Area: Psychedelic Neuroscience
Company profile: USA NASDAQ-listed biotech Phase: 1a SAD MAD & 1b Therapeutic Area: Psychedelic Neuroscience